NJFKQPHGDREVOZ-UHFFFAOYSA-N
C39H45F3N10O2 — CID 90864132
Data last refreshed: (MolForge compound catalog, from PubChem)
About NJFKQPHGDREVOZ-UHFFFAOYSA-N
NJFKQPHGDREVOZ-UHFFFAOYSA-N (PubChem CID 90864132) has the molecular formula C39H45F3N10O2 and a molecular weight of 742.85 g/mol. Its IUPAC name is N-[5-[2-[1-[4-[[5-[2-methyl-6-(trifluoromethyl)-3-pyridinyl]-1H-pyrazol-3-yl]amino]-4-oxobutyl]piperidin-4-yl]quinolin-6-yl]-1H-pyrazol-3-yl]-4-pyrrolidin-1-ylbutanamide.
Molecular Properties
| Compound Name | NJFKQPHGDREVOZ-UHFFFAOYSA-N |
|---|---|
| PubChem CID | 90864132 |
| Molecular Formula | C39H45F3N10O2 |
| Molecular Weight | 742.85 g/mol |
| Exact Mass | 742.37 |
| IUPAC Name | N-[5-[2-[1-[4-[[5-[2-methyl-6-(trifluoromethyl)-3-pyridinyl]-1H-pyrazol-3-yl]amino]-4-oxobutyl]piperidin-4-yl]quinolin-6-yl]-1H-pyrazol-3-yl]-4-pyrrolidin-1-ylbutanamide |
| SMILES | Cc1nc(C(F)(F)F)ccc1-c1cc(NC(=O)CCCN2CCC(c3ccc4cc(-c5cc(NC(=O)CCCN6CCCC6)n[nH]5)ccc4n3)CC2)n[nH]1 |
| InChI | InChI=1S/C39H45F3N10O2/c1-25-29(10-13-34(43-25)39(40,41)42)33-24-36(50-48-33)46-38(54)7-5-19-52-20-14-26(15-21-52)30-11-8-27-22-28(9-12-31(27)44-30)32-23-35(49-47-32)45-37(53)6-4-18-51-16-2-3-17-51/h8-13,22-24,26H,2-7,14-21H2,1H3,(H2,45,47,49,53)(H2,46,48,50,54) |
| InChIKey | NJFKQPHGDREVOZ-UHFFFAOYSA-N |
| XLogP | 7.15 |
| TPSA | 147.82 Ų |
| H-Bond Donors | 4 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 13 |
| Heavy Atoms | 54 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 742.85 |
| LogP ≤ 5 | 7.15 |
| H-Bond Donors ≤ 5 | 4 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 90864132 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.